Related Experiment Video

Updated: Aug 25, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects

Michael C Heinrich1

  • 1Division of Hematology and Medical Oncology, Oregon Health & Science University Cancer Institute; and Portland VA Medical Center, Portland, OR 97201, USA. heinrich@ohsu.edu

Mini Reviews in Medicinal Chemistry
|March 23, 2004
PubMed

Insights

Activating mutations in FLT3 receptor tyrosine kinase are common in acute myelogenous leukemia (AML). Small molecule inhibitors targeting FLT3 kinase activity represent a promising therapeutic strategy for AML patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Activating mutations in the FLT3 receptor tyrosine kinase are the most frequent genetic abnormality in acute myelogenous leukemia (AML).
  • These mutations lead to constitutive FLT3 signaling, contributing to leukemogenesis.
  • FLT3 is a validated therapeutic target in AML.

Purpose of the Study:

  • To review the pre-clinical development of FLT3 inhibitors.
  • To discuss the clinical development of FLT3 inhibitors.
  • To highlight the therapeutic potential of FLT3 inhibition in AML.

Main Methods:

  • Review of pre-clinical studies evaluating FLT3 inhibitors.
  • Analysis of clinical trial data for FLT3 inhibitors in AML.
  • Summary of molecular mechanisms and resistance pathways.

Main Results:

  • Several small molecule FLT3 inhibitors have demonstrated potent pre-clinical activity.
  • Clinical trials have shown promising response rates in AML patients with FLT3 mutations.
  • Emerging resistance mechanisms necessitate further therapeutic strategies.

Conclusions:

  • FLT3 inhibitors represent a significant advancement in AML therapy.
  • Targeting FLT3 offers a viable therapeutic approach for a subset of AML patients.
  • Ongoing research focuses on overcoming resistance and optimizing treatment regimens.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...